PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
์ข
๋ชฉ ์ฝ๋ PMCB
ํ์ฌ ์ด๋ฆPharmaCyte Biotech Inc
์์ฅ์ผSep 11, 2003
CEOSilverman (Joshua N)
์ง์ ์2
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃSep 11
์ฃผ์3960 Howard Hughes Parkway, Suite 500
๋์LAS VEGAS
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ89169
์ ํ19175952850
์น์ฌ์ดํธhttps://pharmacyte.com/
์ข
๋ชฉ ์ฝ๋ PMCB
์์ฅ์ผSep 11, 2003
CEOSilverman (Joshua N)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์